INmune Bio, Inc. to Participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020.

On September 14, 2020 INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported management will participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020 (Press release, INmune Bio, SEP 14, 2020, View Source [SID1234565146]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will be available for virtual one-on-one meetings during the conference. To schedule a meeting with management, please contact your conference representative or [email protected].